Organon (OGN) Divestments (2020 - 2026)

Organon (OGN) posted Divestments of $433.0 million for Q1 2026, up 43200.0% on a QoQ basis from $1.0 million in Q4 2020.

Analysis

Organon (OGN) Divestments (2020 - 2026) Analysis & Trends

Organon has reported Divestments for 2 years, with the latest figure at $433.0 million in Q1 2026.

On a quarterly basis, Divestments changed N/A year-over-year to $433.0 million in Q1 2026; TTM through Jun 2026 was $433.0 million, a N/A change from a year earlier, with the FY2020 full-year figure at -$8.0 million, up 42.86% from the prior year.
Divestments was $433.0 million for Q1 2026 at Organon, up from $1.0 million in the prior quarter.
The five-year high for Divestments was $433.0 million in Q1 2026, with the low at $433.0 million in Q1 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Divestments (Qtr)
1	Johnson & Johnson	641.14 Bn	620.38 Bn	17.26 Bn	-
2	AbbVie	451.04 Bn	444.47 Bn	12.70 Bn	-
3	Merck	357.43 Bn	350.29 Bn	12.21 Bn	-
4	Novartis Ag	266.73 Bn	259.04 Bn	11.24 Bn	62.00 Mn
5	Pfizer	157.52 Bn	145.82 Bn	10.94 Bn	1.88 Bn
6	Sanofi	52.14 Bn	44.76 Bn	10.79 Bn	-
7	Revolution Medicines	42.88 Bn	42.88 Bn	-	-
8	Incyte	24.70 Bn	20.16 Bn	1.57 Bn	-
9	United Therapeutics	21.47 Bn	18.80 Bn	683.80 Mn	-
10	Organon	3.58 Bn	2.45 Bn	847.00 Mn	-

Historic Data

Download Data